Page last updated: 2024-10-31

nalidixic acid and Fanconi Anemia

nalidixic acid has been researched along with Fanconi Anemia in 2 studies

Fanconi Anemia: Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Voter, AF1
Manthei, KA1
Keck, JL1
Rosselli, F1
Duchaud, E1
Averbeck, D1
Moustacchi, E1

Other Studies

2 other studies available for nalidixic acid and Fanconi Anemia

ArticleYear
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
    Journal of biomolecular screening, 2016, Volume: 21, Issue:6

    Topics: Antineoplastic Agents; DNA Damage; DNA Helicases; DNA Repair; Drug Screening Assays, Antitumor; Fanc

2016
Comparison of the effects of DNA topoisomerase inhibitors on lymphoblasts from normal and Fanconi anemia donors.
    Mutation research, 1994, Volume: 325, Issue:4

    Topics: Camptothecin; Cell Division; Cells, Cultured; Chromosome Aberrations; DNA; DNA Damage; DNA Repair; F

1994